Administration and monitoring of anticoagulants in subjects aged over 70 years;Le maniement des anticoagulants chez le sujet de plus de 70 ans

Revue de Geriatrie

Volumn 24, Issue 9, 1999, Pages 733-742

  Siguret, V ^a   Weill Engerer, S ^a   Pautas, E ^a   Gaussem, P ^a  

^a HÔPITAL CHARLES FOIX   (France)

Author keywords

Heparin; Low molecular weight heparin; Vitamine K antagonists

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; FLUINDIONE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PROTOCOL; DRUG CHOICE; DRUG HALF LIFE; ELDERLY CARE; FOLLOW UP; HUMAN; LIFESTYLE; PATIENT MONITORING; RISK BENEFIT ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0033431796     PISSN: 03977927     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. KNIFFIN W.D., BARON J.A., BARRETT J., BIRKMEYER J.D., ANDERSON F.A.: The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994: 154:861-866.
2. LAUPACIS A., ALBERS G.W., DALEN J.E., DUNN M.I., JACOBSON A.K., SINGER D.E.: Antithrombotic therapy in atrial fibrillation. Chest 1998: 114 (suppl): 579S-589S.
3. Recommandations du Groupe d'Etudes sur l'Hémostase et la Thrombose (GEHT). Utilisation des traitements antithrombotiques en pratique médicale courante. Sang Thrombose Vaisseaux 1996: numéro spécial.
4. ANDRE E., SIGURET V., ALHENC-GELAS M., SAINT-JEAN O., GAUSSEM P.: Venous thrombosis in older people: prevalence of the factor V gene mutation Q506. J Am Geriatr Soc 1998: 46: 1545-9.
5. HIRSH J., WARKENTIN T.E., RASCHE R., GRANGER C.B., OHMAN E.M., DALEN J.E.: Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998: 114 (suppl): 489S-510S.
6. CAMPBELL NRC, HULL RD, BRANT R, HOGAN DB, PINEO GF, RASKOB GE.: Aging and heparin-related bleeding. Arch Intern Med. 1996: 156 : 857-860.
7. NICOLAIDES A.N., BERGQVIST D., HULL R. and Faculty. Prevention of venous thromboembolism. International consensus statement. Int Angiol 1997: 16:3-38.
8. KHER A., FIESSINGER J.-N.: Le traitement de la maladie thromboembolique veineuse : bilan et place des héparines de bas poids moléculaire. Sang Thrombose Vaisseaux 1998: 10: 431-438.
9. Comité Scientifique Thrombose de l'AP-HP. Prophylaxie des thromboses veineuses post-opératoires : recommandations de l'Assistance Publique - Hôpitaux de Paris. Sang Thrombose Vaisseaux 1995: 7: 119-129.
10. SAMAMA M.M., COHEN A.T., DARMON J.Y., DESJARDINS L., ELDOR A., JANBON C. et al.: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999 : 341 :793-800.
11. JEANDEL C., BLAIN H.: Le traitement anticoagulant chez le sujet âgé. Presse Med 1998: 27:1453-7.
12. WARKENTIN T.E., LEVINE M.N., , HIRSH J., HORSEWOOD P., ROBERTS R.S., GENT M. et al.: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995: 332: 1330-1335.
13. BONEU B.: Low molecular weight heparin therapy: Is monitoring needed ? Throb Haemost 1994: 72: 330-4.
14. ALHENC-GELAS M., JESTIN-LE GUERNIC C., VITOUX J-F., KHER A., AIACH M., FIESSINGER J.-N.: Adjusted versus fixed doses of the low-molecular-weight-heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994: 71: 698-702.
15. B̂) administered once daily (175 anti-Xa IU/kg) : a pharmacokinetic study over 10 days. Thromb Haemost (soumis).
16. MISMETTI P, LAPORTE-SIMITSIDIS S, NAVARRO C, SIE P., d'AZEMAR P., NECCIARI J., et al.: Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (Nadroparin). Thromb Haemost 1998: 79: 1162-5.
17. HYERS T.M., AGNELLI G., HULL R.D., WEG J.G., MORRIS T.A., SAMAMA M.: Antithrombotic therapy for venous thromboembolic disease. Chest 1998: 114 (suppl): 561S-578S.
18. ADAMS J., GAUTAM P.: Warfarin therapy in the elderly. Brit J Hosp Med 1994: 51: 392-393.
19. FIHN SD, CALLAHAN CM, MARTIN DC, McDONELL MB, HENIKOFF JG, WHITE RH.: The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996: 124: 970-979..
20. LANDELIELD S., BEYTH R.J.: Anticoagulant-related bleeding : clinical epidemiology, prediction, and prevention. Am J Med 1993: 95:315-328.
21. HIRSH J., DALEN J.E., ANDERSON D., POLLER L., BUSSEY H.I., ANSELL J.E. et al.: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998: 114 (suppl): 445S-469S.
22. La Fédération Italienne des Cliniques d'Anticoagulant.: Guide sur le traitement anticoagulant par voie orale (1ère partie). Sang Thrombose Vaisseaux 1998: 10: 291-313.
23. La Fédération Italienne des Cliniques d'Anticoagulant.: Guide sur le traitement anticoagulant par voie orale (2éme partie). Sang Thrombose Vaisseaux 1998: 10: 360-73.
24. REDWOOD M, TAYLOR C, BAIN BJ, MATTHEWS JH.: The association of age with dosage requirement for warfarin. Age and Ageing 1991: 20: 217-220.